ClinicalTrials.gg
Enrolling by invitationNCT07251361SENSORFIT-4HEAUpdated Nov 26, 2025

Effects of a Multicomponent Training Program on Cardiac Function, Skeletal Muscle Metabolism, Functional Capacity, and Quality of Life in Patients With HFpEF: SENSORFIT-4HEART Study

An interventional study of Supervised training in Heart Failure With Preserved Ejection Fraction (HFPEF), sponsored by Universidad Pública de Navarra. Enrolling by invitation at 1 site in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Universidad Pública de Navarra · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jan 2025, registered Sep 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 597 studies in Motor Activity with a site in Spain — 148 open to participants now, 184 under way, 1 of them phase 3. Motor Activity · Spain.

Planned enrollment
134th of 539
150 · median 80
Started
2025
with 76 others
No phase
515 of 597
125 open now
Primary completion
2025-02
later than 25 of 183 live
Registered
509th of 597
by date

Among the 597 studies in Motor Activity with a site in Spain, this one is the 134th largest by planned enrollment of the 539 interventional ones that give a count, is one of 77 that started in 2025, is one of 515 with no phase, reaches primary completion later than 25 of the 183 other live ones, and was the 509th registered.

Motor Activity

9,827 studies on the registry are indexed under Motor Activity; 1,911 are open to participants now.

Browse Motor Activity studies →

Open to participants now

148 of the 597 studies in Motor Activity with a site in Spain are open now. Recruiting first, the newest first:

143 more — sign in →

All 148 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,207 Motor Activity studies recruiting now, 524 (43%) set no upper age limit and 538 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 597 studies in Motor Activity with a site in Spain, or all of them as a file.
02

Study summary

Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome with increasing incidence and poor prognosis, accounting for up to 50% of heart failure cases. It is strongly associated with aging, cardiovascular risk factors (hypertension, diabetes, obesity), and is more prevalent in women than men. Patients with HFpEF frequently present with dyspnea, debilitating fatigue, poor quality of life, frequent hospitalizations, and high mortality rates. This study aims to evaluate the effects of a structured exercise program on cardiac function, skeletal muscle metabolism, functional capacity, and quality of life in patients with HFpEF, and to explore whether these benefits are mediated by circulating exerkines.

Read the detailed description

Standard pharmacological treatments have shown limited prognostic benefit, highlighting the need for non-pharmacological strategies. Exercise training may represent an effective therapeutic tool, with potential to improve cardiac remodeling, skeletal muscle bioenergetics, exercise tolerance, and quality of life. Importantly, exerkines-molecules secreted by skeletal muscle and other organs in response to exercise-may mediate systemic beneficial effects by modulating metabolic, immuno-inflammatory, and growth pathways.

03

Conditions studied

  • Heart Failure With Preserved Ejection Fraction (HFPEF)

Browse trials for

Keywords

  • Exercise
  • PeakVO2
  • Cardiac function
  • Skeletal muscle bioenergetics
  • Quality of life
  • Exerkines
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with heart failure with preserved according to 2021 ESC guidelines for Heart Failure.
  • Left ventricular ejection fraction (LVEF) >40%, and/or evidence of structural and/or functional cardiac abnormality (diastolic dysfunction, elevated filling pressures, >30 kg/m2)
  • Elevated natriuretic peptides (BNP ≥35 pg/mL or NT-proBNP ≥125 pg/mL)
  • Stable symptomatic heart failure patients ( functional class II-III/IV) during the last month

Exclusion criteria

Exclusion Criteria:

  • Participation in cardiac rehabilitation within the past 12 months.
  • to physical exercise training.
  • Alternative diagnoses that could explain symptoms of HF (dyspnea, fatigue), in the judgment of the cardiologist.
  • Significant pulmonary disease, including primary pulmonary hypertension.
  • Severe chronic lung disease, including requiring home oxygen, chronic nebulizer therapy, long-term oral , or hospitalization for decompensated pulmonary disease within the past 12 months.
  • \<10 g/dL.
  • (BMI) >40 kg/m².
  • Inability to perform a valid baseline cardiopulmonary exercise test
  • Inability to comprehend study information or complete questionnaires (e.g., psychiatric disorder, dementia).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Supervised exercise program

    Participants assigned to this arm will receive supervised multicomponent exercise program delivered twice per week, combining resistance training (RT) with aerobic training within the same session. The RT session duration will increase progressively from 10 to 20 min at 40-70 % of one repetition maximum (1-RM) twice weekly. RT include progressively three series × 10-15 repetitions of leg press, knee extensors, chest press, and horizontal rowing.

    Behavioral: Supervised training

  • No intervention
    Usual care

    Patients allocated to this arm will receive the usual care plus explicit recommendations for home-based aerobic and strength training (Vivifrail program).

Interventions

  • BehavioralSupervised training

    Supervised training

06

What researchers measure

Primary outcomes

  1. Peak oxygen consumption

    Changes in peak oxygen consumption between and within groups at 12-week Unit of measure of peak oxygen consumption: mL/kg/min. Maximal functional capacity will be evaluated using incremental and symptom-limited cardiopulmonary exercise testing on a bicycle ergometer, beginning with a workload of 25 W and increasing gradually in a ramp protocol at 25-W increments every 3 minute. We define maximal functional capacity as when the patient stops pedalling because of symptoms and the respiratory exchange ratio (RER) was \>1. Gas exchange data and cardiopulmonary variables were averages of values taken every 10 seconds. Peak oxygen consumption (PeakVO2) was defined as the highest value of VO2 during the last 20 seconds of exercise.

    Time frame: Baseline and 12-week

Secondary outcomes

  1. Lean mass (kg)

    Dual-energy X-ray absorptiometry (DXA) body composition measure

    Time frame: Baseline and 12-week

  2. Changes in blood pressure

    Systolic and diastolic blood pressure of participants in fasting condition will be analyzed by electronic tensiometer and reported in mmHg.

    Time frame: Baseline and 12-week

  3. Changes in Heart rate

    Heart rate of participants in fasting condition will be analyzed by electronic tensiometer and reported in pulses/min.

    Time frame: Baseline and 12-week

  4. Changes in muscle strength

    Grip strength of participants will be measured using a manual dynamometer and reported in kg. Pectoral press, bilateral leg-press, knee extension, and back press) will be measured using a eGYM machines and reported in kg

    Time frame: Baseline and 12-week

  5. Changes in quality of life

    We will use the EuroQol five-dimension five-level questionnaire (EQ-5D-5L) to assess health-related quality of life. The EQ-5D-5L includes five domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each rated on a 5-point scale ranging from 1 (no problems) to 5 (extreme problems). The responses are combined into an index value ranging from -0.594 to 1, where higher scores indicate a better health-related quality of life.

    Time frame: Baseline and 12-week

  6. Physical activity and sedentary behaviour (in minutes)

    Physical activity level objectively measured using Actigraph Accelerometry. This will be worn on the waist and will passively record physical activity and sedentary behavior.

    Time frame: Baseline and 12-week

  7. Pittsburgh Sleep Quality Index

    A 19-item self-report questionnaire that assesses subjective sleep quality and disturbances over the past month will be evaluated by Pittsburgh Sleep Quality Index. The global score ranges from 0 to 21, with higher scores indicating poorer sleep quality.

    Time frame: Baseline and 12-week

  8. Epidemiological Studies-Depression Scale questionnaire

    Depression levels will be assessed using the Center for Epidemiological Studies-Depression Scale (CES-D) questionnaire, which is validated and widely employed in cardiometabolic patients. The CES-D consists of 20 items, each rated on a 4-point Likert scale ranging from 0 (rarely or none of the time) to 3 (most or all of the time), assessing the frequency of depressive symptoms during the past week. The total score ranges from 0 to 60, with higher scores indicating greater depressive symptomatology.

    Time frame: Baseline and 12-week

  9. Cognitive Function

    Global cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA), a validated screening tool that evaluates multiple cognitive domains, including executive function, memory, attention, language, and visuospatial abilities. The total score ranges from 0 to 30, with higher scores indicating better cognitive performance.

    Time frame: Baseline and 12-week

  10. Adherence to the Mediterranean Diet

    Adherence to the Mediterranean dietary pattern will be assessed using the Mediterranean Diet Adherence Screener (MEDAS), a validated 14-item questionnaire designed to evaluate compliance with key components of the Mediterranean diet. Each item is scored 0 or 1, depending on whether the dietary criterion is met, yielding a total score ranging from 0 to 14, where higher scores indicate greater adherence to the Mediterranean diet.

    Time frame: Baseline and 12-week

  11. Psychological Distress

    The Kessler Psychological Distress Scale (K10) will be used to assess nonspecific psychological distress, including symptoms of anxiety and depression, experienced over the past four weeks. The K10 consists of 10 items, each rated on a 5-point Likert scale ranging from 1 (none of the time) to 5 (all of the time), resulting in a total score between 10 and 50. Higher scores indicate greater psychological distress.

    Time frame: Baseline and 12-week

  12. Haematology

    Erythrocyte count (×10⁶ cells/µL), haematocrit (%), haemoglobin (g/dL), platelet count (×10³ cells/µL), leukocyte count (×10³ cells/µL), and erythrocyte mean corpuscular volume (fL) will be quantified using a Coulter haematology analyzer (Brand, City, Country).

    Time frame: Baseline and 12-week

  13. Concentrations of circulating cytokines, adipokines, myokines, and bone metabolism biomarkers.

    Plasma concentrations of pro-inflammatory and anti-inflammatory cytokines (IL-1β, IL-2, IL-6, IL-8, IL-10, IFN-γ, TNF-α, IL-1ra, and TNF sRII-α), adipokines (adiponectin, adipsin, resistin, PAI-1 active, insulin, and leptin), and myokines (irisin) will be quantified using Luminex xMAP technology. In addition, biomarkers related to bone metabolism (ACTH, DKK-1, FGF-23, osteocalcin, osteopontin \[OPN\], osteoprotegerin, PTH, and sclerostin \[SOST\]) will be measured with the same platform. Each analyte will be reported separately as an independent outcome, with concentrations expressed in pg/mL or ng/mL, as appropriate for the specific biomarker.

    Time frame: Baseline and 12-week

  14. Resting energy expenditure

    Resting energy expenditure is measured in the fasting and fed state by indirect calorimetry

    Time frame: Baseline and 12-week

  15. N-terminal pro-B-type natriuretic peptide (NT-proBNP)

    N-terminal pro-B-type natriuretic peptide (NT-proBNP) will be quantified by standardized immunoassay (e.g., electrochemiluminescence immunoassay, ECLIA) following manufacturer's instructions

    Time frame: Baseline and 12-week

  16. Lean mass index (kg/m2)

    Dual-energy X-ray absorptiometry (DXA) body composition measure

    Time frame: Baseline and 12-week

  17. Appendicular lean mass index (kg/m2)

    Dual-energy X-ray absorptiometry (DXA) body composition measure

    Time frame: Baseline and 12-week

  18. Fat mass index (kg/m2)

    Dual-energy X-ray absorptiometry (DXA) body composition measure

    Time frame: Baseline and 12-week

  19. Fat mass (kg)

    Dual-energy X-ray absorptiometry (DXA) body composition measure

    Time frame: Baseline and 12-week

  20. Visceral adipose tissue (kg)

    Dual-energy X-ray absorptiometry (DXA) body composition measure

    Time frame: Baseline and 12-week

  21. Lean mass/fat mass ratio

    Dual-energy X-ray absorptiometry (DXA) body composition measure

    Time frame: Baseline and 12-week

  22. Fat free mass

    Dual-energy X-ray absorptiometry (DXA) body composition measure

    Time frame: Baseline and 12-week

  23. Whole bone mineral density (g/cm2)

    Dual-energy X-ray absorptiometry (DXA) body composition measure

    Time frame: Baseline and 12-week

Other outcomes

  1. Lipidomic

    Lipidomic will be expressed and analyzed in plasma and serum according to their intensity measured in arbitrary units (UA), which carries a direct relation with its concentration in blood. Performed in a randomly selected sub-sample of approximately 30% of study participants

    Time frame: Baseline and 12-week

  2. Mitochondrial leak respiration

    Mitochondrial O2 flux is measured by high-resolution respirometry in muscle mass tissue. Performed in a randomly selected sub-sample of approximately 30% of study participants

    Time frame: Baseline and 12-week

  3. Proteome profile

    Assessment of changes in proteins profile following intervention in blood. Performed in a randomly selected sub-sample of approximately 30% of study participants. Each outcome will be reported separately, with concentrations expressed in pg/mL or ng/mL, as appropriate for the specific analyte.

    Time frame: Baseline and 12-week

07

Study locations

1 site
  • Universidad Pública de Navarra (UPNA)
    Pamplona, Navarre 31010, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Feb 2025, 0 months.

Of 5,176 non-industry interventional studies with no phase under Motor Activity, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's 0 months is below that.

Counting every sponsor, half of 5,236 studies reached it within 17 months; a quarter within 7 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2025
First posted
Nov 26, 2025
StartActual
Jan 20, 2025
Primary completionActual
Feb 1, 2025
CompletionEst.
Dec 20, 2026
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07251361
Lead sponsor
Universidad Pública de Navarra
Collaborators
NavarraBiomed Biomedical Research Center, Centro de Investigación Médica Aplicada (CIMA), Complejo Hospitalario de Navarra, Fundación Instituto de Investigación Sanitaria de Navarra
Responsible party
Dr Mikel Izquierdo (Principal Investigator, Universidad Pública de Navarra) — Principal investigator
First posted
Nov 26, 2025
Start date
Jan 20, 2025
Primary completion
Feb 1, 2025
Completion
Dec 20, 2026 (estimated)
Last update
Nov 26, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion